The 21st Biosimilars Congregation 2026 is a conference that examines strategic, clinical, regulatory, manufacturing, and market access developments shaping the global biosimilars landscape.
Key Topics
Trends & Strategies
Market dynamics, challenges, competitive landscape, and emerging ventures
Current trends and strategies to access the biosimilar market
Barriers to formulary inclusion, health equity, and biosimilar market entry
Clinical Development
Key issues and updates in biosimilar clinical development
Manufacturing
Reducing costs, optimizing development, and navigating pricing pressures
Developmental challenges in biosimilar manufacturing
Research & Development (R&D)
Interchangeability studies and enhancements in R&D models
Growth in biosimilar R&D, future demand, and success rates
Market Access
Negotiating access, payer influence, and best practices
Product launch strategies, sustainability challenges, and market exclusivity
Regulatory
Regulatory shifts, approval pathways, and interchangeability
Evolving regulatory framework for biosimilars approval
Real-World Evidence (RWE)
RWE studies, data sources, and market penetration strategies
Future evidence requirements for biosimilars registration
